Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Aclarion, Inc.

The first, evidence-supported, SaaS platform to leverage MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.

Tech Coast Angels

Aclarion

Chronic low back pain is a life-changing condition that prevents many individuals from living full and healthy lives. And finding the right treatment option for each patient’s unique situation can take months, if not years, to find. 
 
With Nociscan, patient-specific biomarker data helps physicians quickly assess which discs are potentially the source of a patient’s pain so physicians can optimize treatment strategies and help patients get back to an active, pain-free life.
 
Patients around the world are already experiencing the benefits of Nociscan. To learn more about how Nociscan can help you or a loved one, visit www.aclarion.com.
 
#ACON #ACONW #spine #nasdaq #lowbackpain

Last weekend at ISASS 2023, Leslie Wilson presented a cost-effectiveness abstract overviewing the initial findings of the EVAL study (Economic Value Analysis of Low back pain). The study found that Nociscan demonstrated statistical dominance over provocative discography with the potential to save the US healthcare system $283M to $441M annually. Read the full release here. https://lnkd.in/gMNt2uMw

#ACON #ACONW #nasdaq #lowbackpain #nociscan #spinesurgery #ISASS

New and compelling healthcare economics data from the EVAL Study (Economic Value Analysis of Low back pain Study) will be presented this week at ISASS 2023 in San Francisco! 

Join Aclarion on Saturday, June 3 in Salon 13-15 at 10:34 am to learn about the initial findings of this pivotal economic analysis of the Nociscan solution for the treatment of low back pain. 

Presentation title: Cost-effectiveness of novel, non-invasive diagnostic test for chronic low back pain. 
Presenter: Leslie Wilson, Professor at UCSF. 

#ACON #ACONW #ISASS23 #lowbackpain #spinesurgery #nasdaq

Aclarion announced today their commercial agreement with the prestigious London Clinic and London Spine Clinic. The London Clinic is one of the UK’s largest and most renowned independent hospitals. Based in the heart of London’s medical district, the Clinic has a heritage of investing in the latest technologies and providing exceptional medical care through state-of-the-art facilities.

“The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options available to them.  Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis,” said John Sutcliffe MD, Neurosurgeon, and Founder of London Spine Clinic.

Read the full announcement here. https://lnkd.in/gAmfkDQT

#ACON #ACONW #nasdaq #londonspineclinic #londonclinic #nociscan #spinesurgery

Aclarion’s CEO Brent Ness was recently interviewed by Proactive about the value of the Nociscan solution when treating patients with chronic low back pain and the corporate milestones that the company has recently achieved. Watch the full interview here. https://lnkd.in/gzEPAhkm

#ACON #ACONW #nasdaq #nociscan #lowbackpain #spine #spinesurgery

Wonderful Aclarion symposium today at SpineWeek in Melbourne. Standing room only to hear spine experts Sigurd Berven MD and Jeff Lotz PhD discuss the value of the Nociscan solution in addressing the question of Where’s the Pain? The clinical and economic data are clear: Nociscan improves clinical outcomes and has the potential to significantly reduce the cost of care. Visit www.aclarion.com to learn how you can bring Nociscan to your spine center. 

#ACON #ACONW #nasdaq #spineweek #painmanagement #pain #nociscan #spinesurgery

Attending SpineWeek in Melbourne next week? If so, join us Tuesday, May 2 for a sponsored symposium, Where’s The Pain?, led by renowned spine experts Sigurd Berven, MD and Jeff Lotz, PhD. New clinical and economic data will be presented demonstrating the value of the Nociscan solution to aid in the treatment of chronic low back pain. Hope to see you there.

#ACON #ACONW #nociscan #spineweek #spine #nasdaq #pain #painmanagement

We’re excited to announce the publication of two-year durability data which demonstrates improved surgical outcomes for discogenic low back pain (DLBP) surgeries at chemically painful lumbar discs identified by Nociscan. Success rates at 2 years for DLBP low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs. (85% vs. 63%; p=0.07). Access the full article at https://lnkd.in/dCREgnkE

#ACON #ACONW #spinesurgery #nociscan #lowbackpain

Great debate last Friday at the 2023 Annual AANS/CNS Spine Summit between Juan Uribe, MD and Christopher Ames, MD on the role of AI and ML in spine surgery. Important topics raised by both sides and clearly, the future of spine care will be influenced by this growing field. 

Thank you, Dr. Uribe and Dr. Ames, for your continued commitment to advancing care for patients suffering from chronic low back pain.

#ACON #ACONW #spine #AI #machinelearning

Great topic for a debate! Looking forward to tomorrow's discussion.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory				150.67K -
average payables		680.28K -	959.54K 41.05%	758.55K 20.95%
average receivables		18.60K -	14.39K 22.62%	12.42K 13.66%
book value per share	-0.22 -	-0.91 316.21%	-0.80 11.89%	0.29 136.70%
capex per share	-0.03 -	-0.02 33.00%	-0.02 7.51%	-0.03 61.61%
capex to depreciation	-1.50 -	-0.91 39.17%	-0.80 12.00%	-1.08 34.40%
capex to operating cash flow	0.06 -	0.05 26.37%	0.06 37.13%	0.04 39.24%
capex to revenue	-9.93 -	-3.68 62.96%	-2.52 31.49%	-3.46 37.06%
cash per share	0.02 -	0.00 88.31%	0.06 3,189.87%	0.24 282.77%
days of inventory on hand				1.68K -
days payables outstanding	2.89K -	4.74K 63.61%	5.59K 18.05%	2.56K 54.25%
days sales outstanding	199.42 -	168.82 15.34%	38.02 77.48%	112.13 194.94%
debt to assets	0.36 -	1.84 410.51%	1.06 42.47%
debt to equity	-0.30 -	-0.34 10.77%	-0.35 4.04%
dividend yield				0.12 -
earnings yield	-0.19 -	-0.23 19.04%	-0.18 19.62%	-2.57 1,321.82%	-2.76 7.13%
enterprise value	21.66M -	23.64M 9.11%	21.08M 10.83%	2.07M 90.19%
enterprise value over ebitda	-5.65 -	-5.52 2.27%	-4.53 17.98%	-0.35 92.26%
ev to operating cash flow	-5.19 -	-6.23 19.92%	-8.97 44.03%	-0.39 95.66%
ev to sales	805.43 -	485.86 39.68%	349.62 28.04%	34.22 90.21%
free cash flow per share	-0.57 -	-0.51 10.45%	-0.35 31.43%	-0.90 159.62%	-6.55 624.06%
free cash flow yield	-0.21 -	-0.19 10.45%	-0.13 31.43%	-1.56 1,117.53%	-2.05 31.24%
graham net net	-0.38 -	-1.07 178.75%	-1.00 6.50%	0.04 103.60%
graham number	1.59 -	3.53 122.59%	2.97 15.85%	3.14 5.48%
income quality	1.04 -	0.82 21.10%	0.47 42.03%	0.70 47.19%	0.74 6.27%
intangibles to total assets	0.81 -	0.90 11.27%	0.61 33.06%	0.38 37.47%	0 100%
interest coverage	-803.46 -	-28.69 96.43%	-6.20 78.40%	-4.05 34.73%	8.02 298.15%
interest debt per share	0.07 -	0.32 386.58%	0.34 6.51%	0.25 28.41%
inventory turnover				0.22 -
invested capital	-0.30 -	-0.34 10.77%	-0.35 4.04%
market cap	21.28M -	21.28M 0%	19.53M 8.20%	3.54M 81.87%	1.78M 49.68%
net current asset value	-2.91M -	-8.28M 184.10%	-6.89M 16.81%	570.03K 108.28%
net debt to ebitda	-0.10 -	-0.55 446.08%	-0.33 39.74%	0.25 175.08%
net income per share	-0.51 -	-0.61 19.04%	-0.49 19.62%	-1.49 203.18%	-8.82 491.05%
operating cash flow per share	-0.53 -	-0.49 9.01%	-0.33 32.55%	-0.87 165.96%	-6.55 652.51%
payables turnover	0.13 -	0.08 38.88%	0.07 15.29%	0.14 118.59%
receivables turnover	1.83 -	2.16 18.13%	9.60 344.04%	3.26 66.09%
research and ddevelopement to revenue	64.57 -	21.63 66.51%	13.07 39.58%	18.01 37.85%	11.58 35.70%
return on tangible assets	-15.07 -	-39.03 158.96%	-4.75 87.84%	-4.58 3.59%
revenue per share	0.00 -	0.01 80.88%	0.01 34.99%	0.01 17.91%	0.14 1,267.92%
roe	2.36 -	0.68 71.40%	0.62 8.77%	-5.10 926.15%
roic	3.39 -	0.98 70.97%	0.57 42.49%	-4.09 822.84%
sales general and administrative to revenue	58.98 -	22.02 62.67%	30.28 37.49%	73.92 144.13%	43.04 41.77%
shareholders equity per share	-0.22 -	-0.91 316.21%	-0.80 11.89%	0.29 136.70%
stock based compensation to revenue	1.04 -	0.54 48.48%	2.94 448.07%	21.32 624.22%	6.05 71.63%
tangible asset value	-2.87M -	-8.25M 188.02%	-6.87M 16.71%	573.38K 108.34%
tangible book value per share	-0.37 -	-1.06 188.02%	-0.96 9.27%	0.09 109.81%
working capital	-2.91M -	-8.28M 184.10%	-6.89M 16.81%	570.03K 108.28%

COM:ACLARION

Aclarion, Inc.

Last Close

0.18

22/11 21:00

Market Cap

2.49M

Beta: -

Volume Today

124.21K

Avg: -

Preview